Does Timing Matter? What Research Found About Starting Menopause Hormone Therapy
For many women, the words "hormone therapy" still bring back the headlines of 2002. That year, early results from the Women's Health Initiative (WHI), a large American trial, showed no heart benefit from hormone therapy [1]. Many women stopped treatment. Since then, researchers have asked a sharper question: does the effect depend on when a woman starts? This is called the timing hypothesis. Here is what the research shows, and where it still falls short.
Why the early results puzzled researchers
Before the WHI, many observational studies had linked hormone therapy with less heart disease. Observational studies follow what people already do. Randomised trials, which assign treatment by chance, are stronger evidence, and they did not show the same benefit [2].
Age was one clue. In the observational studies, women usually started hormones at about 50, often within two years of their last period. In the major trials, women were mostly in their 60s and more than ten years past menopause [2]. The average WHI participant was 63 when she joined [3]. So the studies may have been asking different questions: what estrogen does to arteries that are still fairly healthy, and what it does to arteries that have already changed.
Why the starting point may matter
The timing idea is that estrogen's effect on arteries depends on their condition when treatment begins. It may also depend on whether the artery walls still have enough estrogen receptors, the docking sites that let cells respond to the hormone [2].
Animal research fits this idea. In primates and other animals, estrogen slowed the build-up of plaque, the fatty deposits that narrow arteries, when it was started at menopause. It did not help when started later, and it did not remove plaque that was already there [2]. Animal studies suggest how something might work. They do not prove it in people.
What three major studies found
The Danish trial (DOPS). Researchers enrolled 1,006 healthy Danish women. On average they were 50 years old and seven months past menopause. Half received hormone therapy and half received none, for about ten years. The researchers counted deaths, hospital stays for heart failure, and heart attacks together. These happened to 16 women on hormones and 33 women without, about half as often. Cancer rates did not differ clearly. The difference was still there after 16 years [1].
The ELITE trial. This was the first trial built specifically to test the timing idea [2]. It included 643 healthy women in two groups: those fewer than six years past menopause, and those ten or more years past. Each woman received estradiol, the main estrogen the ovaries make, or a placebo (a dummy treatment). Women with a uterus also received progesterone or a matching placebo. Every six months, an ultrasound measured the inner wall of the main neck artery. A thickening wall is an early, silent sign of artery hardening.
After about five years, timing made the difference. In women who started within six years of menopause, the artery wall thickened more slowly with estradiol than with placebo. In women who started ten or more years after menopause, there was no difference [2].
The WHI, 18 years later. In 2017, WHI researchers looked at deaths over 18 years among 27,347 women aged 50 to 79. Overall, death rates were almost the same with hormone therapy and placebo: 27.1% and 27.6% [3]. Women who started in their 50s did better than women who started in their 70s, mainly during the years they were on treatment. That gap became smaller over time [3].
What the guidelines say now
The North American Menopause Society's 2022 statement says that for healthy women under 60, or within ten years of menopause, the benefits generally outweigh the risks when treating bothersome hot flushes and bone loss after menopause. For women who start later, the balance looks less favourable [4]. The International Menopause Society's 2026 recommendations reach a similar view on starting before 60 or within ten years of menopause. It treats heart findings as one factor to weigh, not a reason on its own to start [5].
Physicians who focus on optimal hormone levels look at estrogen alongside the body's other hormones. You can read more on our Hormone Health page.
What the evidence can't tell us yet
The timing research is encouraging, but it has limits:
ELITE measured artery walls, not heart attacks or strokes. Heart scans at the end of the trial showed no clear difference in either group [2].
DOPS was fairly small, and everyone knew who was taking hormones, which can affect results [1]. When combined analyses leave out trials like this, the heart benefit in younger women is no longer clear [4].
The WHI age results come from comparing smaller groups within the trial, and they weakened over time. The WHI authors said their results do not support using hormone therapy to prevent chronic disease [3]. The US Preventive Services Task Force agrees for women without symptoms. Its advice does not cover women treating menopause symptoms, or women with early or surgical menopause [6].
ELITE and the WHI used estrogen tablets [2,4]. A trial of lower-dose estrogen, including a skin patch, found no effect on artery walls [4]. Tablets, gels and patches have not been compared head to head, and most trials included North American and European women [4].
What to talk about with your doctor before starting
Your symptoms. Hot flushes, night sweats, sleep and bone health are the main reasons guidelines support treatment [4].
Your timing. Your age and the time since your last period shape the balance of benefits and risks [4].
Your history. Mention any personal or family history of heart disease, stroke, blood clots or breast cancer, and any unexplained vaginal bleeding or liver disease [4].
Your uterus. If you have one, estrogen needs to be paired with a progestogen, a hormone that protects the womb lining [4].
Regular review. Guidelines advise checking from time to time whether treatment still suits you [4].
Your doctor sets the dose and chooses the type of treatment with you.
The question is no longer simply whether hormone therapy is good or bad. It is who it suits, and when. To see how estrogen fits into a wider hormone check, visit our Hormone Health page.
Reviewed by Dr. Panapon Lumdee, MD · Last reviewed: 9 November 2026
References
Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409.
Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ, Hwang-Levine J, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221-31.
Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA. 2017;318(10):927-38.
The North American Menopause Society. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-94.
Panay N, Fenton A, Hamoda H, Hillard T, Islam R, Pedder H, et al. International Menopause Society (IMS) recommendations and key messages on women's midlife health and menopause [Internet]. International Menopause Society; 2026.
US Preventive Services Task Force. Hormone therapy for the primary prevention of chronic conditions in postmenopausal persons: clinician summary of USPSTF recommendation [Internet]. US Preventive Services Task Force; 2022 Nov.



Comments